Vimarsana
Biggest News Aggregation in the World

Page 7 - Practice Guidelines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Practice Guidelines Today - Breaking & Trending Today

AstraZeneca : Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -April 05, 2024 at 08:38 pm EDT - Vimarsana News

AstraZeneca : Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -April 05, 2024 at 08:38 pm EDT

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours ...

Clinical Quiz: Gastrointestinal Evaluation of Iron Deficiency Anemia - Vimarsana News

Clinical Quiz: Gastrointestinal Evaluation of Iron Deficiency Anemia

This clinical quiz will test your knowledge of iron deficiency anemia, focused on the gastrointestinal evaluation of anemia based on recommendations from the AGA's 2020 guidelines.

Investigation finds no evidence Medical Examiner 'butchered' bodies during autopsy - Vimarsana News

Investigation finds no evidence Medical Examiner 'butchered' bodies during autopsy

Investigations by the Medical Examiners Commission and Florida Department of Law Enforcement found no evidence of wrongdoing by the medical examiner.

Source: yahoo.com
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status - Vimarsana News

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in...

"Review of the literature supporting international clinical practice gu" by Laurencia Maria Villalba, Iman Bayat et al. - Vimarsana News

"Review of the literature supporting international clinical practice gu" by Laurencia Maria Villalba, Iman Bayat et al.

Background: The overall goal of this report is to provide a high-level, practical approach to managing venous outflow obstruction (VOO). Methods: A group of vascular surgeons from Australia and New Zealand with specific interest, training, and experience in the management of VOO were surveyed to assess current local practices. The results were analyzed and areas of disagreement identified. After this, the group performed a literature review of consensus guidelines published by leading international organizations focused on the management of chronic venous disease, namely, the Society for Vascu...

Source: uow.edu.au